CONSOLIDATED BALANCE SHEETS [Abstract] Total current assets Total assets Debt Instrument [Axis] Total current liabilities Total liabilities Total stockholders' equity Balance Balance Total liabilities and stockholders’ equity CONSOLIDATED STATEMENTS OF OPERATIONS [Abstract] Product and Service [Axis] Total operating expenses Loss from operations Loss before income tax expense Net loss Net loss CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS [Abstract] Comprehensive loss CONSOLIDATED STATEMENTS OF STOCKHOLDERS [Abstract] Balance (in Shares) Balance (in Shares) Equity Components [Axis] CONSOLIDATED STATEMENTS OF CASH FLOWS [Abstract] Net cash used in operating activities Net cash provided by investing activities Net cash provided by financing activities Net increase (decrease) in cash and cash equivalents Cash and cash equivalents at beginning of period Cash and cash equivalents at end of period Organization and Basis of Presentation [Abstract] Significant Accounting Policies [Abstract] Supplemental Financial Data [Abstract] Inventory [Abstract] Total Statement of Financial Position Location, Balance [Axis] Accrued Liabilities [Abstract] Total accrued liabilities Accrued liabilities Revenues [Abstract] Revenue: Collaborative Arrangements and Licensing Agreements [Abstract] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Concentration Risk Benchmark [Axis] Concentration Risk Type [Axis] Concentration percentage Concentration percentage Basic and Diluted Net Loss Per Share [Abstract] Investments [Abstract] Total Financial Instrument [Axis] Amortized cost Amortized cost Amortized cost Gross unrealized gains Gross unrealized losses Estimated fair value Available-for-sale securities Amortized cost Amortized cost Gross unrealized gains Gross unrealized losses Estimated fair value Total temporary impairment Total temporary impairment Fair Value Measurements [Abstract] Total Measurement Frequency [Axis] Fair Value Hierarchy and NAV [Axis] Stock-based Compensation Expense [Abstract] Statement of Income Location, Balance [Axis] Total stock-based compensation expense Grantee Status [Axis] Liability Related to Sale of Future Royalties [Abstract] Liability related to sale of future royalties, net Liability related to sale of future royalties, net Convertible Debt [Abstract] Legal Proceedings [Abstract] Segment Information [Abstract] Segments [Axis] Eric Swayze [Member] Termination [Member] Holly Kordasiewicz [Member] Adoption [Member] Frank Bennett [Member] Document Type Document Quarterly Report Current Fiscal Year End Date Document Period End Date Document Fiscal Year Focus Document Transition Report Entity File Number Entity Registrant Name Entity Incorporation, State or Country Code Entity Tax Identification Number Entity Address, Address Line One Entity Address, City or Town Entity Address, State or Province Entity Address, Postal Zip Code City Area Code Local Phone Number Title of 12(b) Security Trading Symbol Security Exchange Name Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Entity Shell Company Entity Common Stock, Shares Outstanding Entity Central Index Key Amendment Flag Document Fiscal Period Focus ASSETS Current assets: Cash and cash equivalents Short-term investments Escrow deposit for maturity of 0 percent convertible senior notes due April 2026 Escrow deposit (in Dollars) Contracts receivable Inventories Other current assets Property, plant and equipment, net Right-of-use assets Deposits and other assets LIABILITIES AND STOCKHOLDERS’ EQUITY Current liabilities: Accounts payable Accrued compensation Income taxes payable 0 percent convertible senior notes due April 2026 Interest rate on convertible senior notes Interest rate Current portion of deferred contract revenue Other current liabilities Long-term deferred contract revenue Convertible senior notes, net Liability related to sale of future royalties, net Liability related to sale of future royalties, net - Non-current Long-term lease liabilities Long-term obligations Stockholders’ equity: Common stock, $0.001 par value; 300,000,000 shares authorized, 165,902,064 and 163,304,875 shares issued and outstanding at March 31, 2026 and December 31, 2025, respectively Common stock, par value (in Dollars per share) (in Dollars per share) Common stock, shares authorized (in Shares) (in Shares) Common stock, shares issued (in Shares) (in Shares) Common stock, shares outstanding (in Shares) (in Shares) Additional paid-in capital Accumulated other comprehensive loss Accumulated deficit Revenue Expenses: Cost of sales Research, development and patent Selling, general and administrative Other income (expense): Investment income Gain (loss) on investments, net Other income (expense), net Basic net loss per share (in Dollars per share) Diluted net loss per share (in Dollars per share) Shares used in computing basic net loss per share (in Shares) Shares used in computing diluted net loss per share (in Shares) Unrealized gains (losses) on debt securities, net of tax Change in unrealized gains (losses), net of tax Currency translation adjustment Foreign currency translation Issuance of common stock in connection with employee stock plans, net Issuance of common stock in connection with employee stock plans, net (in Shares) Stock-based compensation expense Operating activities: Adjustments to reconcile net loss to net cash used in operating activities: Depreciation Amortization of right-of-use operating lease assets Amortization of other assets Amortization of debt issuance costs Non-cash interest related to sale of future royalties Interest expense related to sale of future royalties Stock-based compensation expense Non-cash losses related to other assets Changes in operating assets and liabilities: Accounts payable Income taxes Accrued compensation Accrued liabilities and other liabilities Deferred contract revenue Investing activities: Proceeds from sale of short-term investments Financing activities: Proceeds from issuance of common stock through equity plans, net Effects of exchange rates on cash Supplemental disclosures of cash flow information: Interest paid Income tax refunds received, net Supplemental disclosures of non-cash investing and financing activities: Amounts accrued for capital and patent expenditures Interest expense Interest expense related to sale of future royalties Income tax expense Amortization of discount on investments, net Non-cash royalty revenue related to sale of royalties Royalty payments to Royalty Pharma Loss (gain) on investments, net Escrow deposit for maturity of 0 percent convertible senior notes due April 2026